Immunohistochemical survey of p16(INK4A) expression in normal human adult and infant tissues

Laboratory Investigation

Volumn 79, Issue 9, 1999, Pages 1137-1143

  Nielsen, Gunnlaugur P ^a   Stemmer Rachamimov, Anat O ^a   Shaw, Joan ^a   Roy, Jennifer E ^a   Koh, Jim ^b,c   Louis, David N ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Massachusetts Central Hospital East   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P16INK4A;

ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENESCENCE; TISSUE DISTRIBUTION; TUMOR CELL LINE; ADULT; CELL DIFFERENTIATION; CELL DIVISION; NEWBORN; PHYSIOLOGY; REFERENCE VALUE;

ADULT; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; REFERENCE VALUES;

EID: 0032589106     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Burns KL, Ueki K, Jhung SL, Koh J, and Louis DN (1998). Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122-130.
2. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32.
3. Cayuela JM, Hebert J, and Sigaux F (1995). Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood 85:854.
4. Corless CL, Kibel AS, Iliopoulos O, and Kaelin WG (1997). Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28:459-464.
5. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, and Brambilla E (1998). Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16:497-504.
6. George A and Ritter M (1996). Thymic involution with aging: Obsolescence or good housekeeping? Immunol Today 17: 267-272.
7. Geradts J, Kratzke RA, Niehans GA, and Lincoln CE (1995). Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2 multiple tumor suppressor gene 1 (CDKN2 MTS1) product p16INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011.
8. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr., and Tucker MA (1995). Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974.
9. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Turnout JM, Jones PA (1995). Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
10. Hall M and Peters G (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108.
11. Hara E, Smith R, Parry D, Tahara H, Stone S, and Peters G (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16:859-867.
12. Hebert J, Cayuela JM, Berkeley J, and Sigaux F (1994). Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038-4044.
13. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. Science 253:49-53.
14. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994). Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
16. Levine AJ, Momand J, and Finlay CA (1991). The p53 tumour suppressor gene. Nature 351:453-456.
17. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, and Voest EE (1996). Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75:231-238.
18. Louis DN, Edgerton S, Thor AD, and Hedley-Whyte ET (1991). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathol (Berl) 81:675-679.
19. Mori T, Miura K, Aoki T, Nishihira T, Mori S, and Nakamura Y (1994). Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397.
20. Nielsen GP, Burns KL, Rosenberg AE, and Louis DN (1998). CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that RB alterations. Am J Pathol 153:159-165.
21. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FC, Weston A, Modali R, Harris CC, and Vogelstein B (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
22. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, and Carson DA (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
23. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN (1996). Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki 67 proliferation indices. J Neuropathol Exp Neurol 55:1026-1031.
24. Palmero I, McConnell B, Parry D, Brookes S, Hara E, Bates S, Jat P, Peters G (1997). Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 15:495-503.
25. Quelle D, Zindy F, Ashmun R, and Sherr C (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
26. Reich NC and Levine AJ (1984). Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308:199-201.
27. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, and Stadler WM (1996). Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-2890.
28. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130.
29. Serrano M, Hannon G, and Beach D (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
30. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, and DePinho RA (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
31. Sherr CJ (1996). Cancer cell cycles. Science 274:1672-1677.
32. Short MP, Richardson EP, Haines JL, and Kwiatkowski DJ (1995). Clinical, neuropathological and genetic aspects of the tuberous sclerosis complex. Brain Pathol 5:173-179.
33. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J, Lee E, Miyoshi I, and Koeffler HP (1995). Analysis of a family of cyclin-dependent kinase inhibitors: P15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86:755-760.
34. Ueki K, Ono Y, Henson J, von Deimling A, and Louis DN (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153.
35. Uhrbom L, Nister M, and Westermark B (1997). Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15:505-514.
36. Wienecke R, Maize JC, Reed JA, de Gunzburg J, Yeung RS, and DeClue JE (1997). Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues. Am J Pathol 150:43-50.
37. Zbar B (1995). Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 25:219-232.
38. Zindy F, Quelle D, Roussel M, and Sherr C (1997). Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-211.